a2z Radiology AI Raises $4.5 Million Seed to Expand AI-Powered Comprehensive CT Interpretation
a2z Radiology AI, a Boston-based medical imaging artificial intelligence company, has raised $4.5 million in seed funding to accelerate the commercial rollout of its AI-driven imaging interpretation tools and support continued research and development of broader capabilities. The round comes as the company advances its first FDA-cleared product — an AI-powered triage system designed to help clinicians interpret complex CT scans more comprehensively and efficiently.
The seed financing was co-led by Khosla Ventures, a prominent venture capital firm known for early bets on technology and healthcare innovators, and SeaX Ventures, a global deep-tech venture capital firm that supports startups deploying transformative technologies across industries. Together, these investors are providing strategic capital and expertise to support a2z Radiology AI’s growth and product expansion.
Founded in 2024 by co-founders Pranav Rajpurkar, PhD, and Samir Rajpurkar, a2z Radiology AI focuses on building the “intelligence layer” for medical imaging by creating AI systems that deliver immediate, radiologist-level interpretation of scans. The company’s initial commercial product, a2z‑Unified‑Triage, earned clearance from the U.S. Food and Drug Administration and represents a milestone in the application of generalist AI to medical imaging. Unlike many existing tools that target individual conditions, a2z’s approach evaluates CT scans holistically, identifying multiple critical findings from a single study — a closer approximation of how human radiologists analyze medical images.
The new funding will be used to accelerate partnerships with health systems, expand deployment of the FDA-cleared triage system, and support continued development of additional AI tools capable of comprehensive interpretation across imaging modalities and anatomies. a2z’s vision encompasses delivering scalable AI solutions that can assist clinicians in reducing turnaround times, prioritizing urgent cases, and improving diagnostic accuracy by automating elements of the interpretation workflow.
a2z Radiology AI’s seed round follows the company’s successful debut at RSNA 2025, where it presented initial clinical evidence showing real-world performance benefits of its AI tools. Early data highlighted that AI-assisted interpretation reduced reporting times while increasing radiologist confidence and decreasing cognitive workload during assessment of abdominal and pelvic CT scans. These findings helped validate the practical value of comprehensive AI in clinical settings and underscore investor interest in backing scalable healthcare AI technologies.
Imaging demand continues to outpace available radiology expertise, particularly for high-volume modalities such as abdomen-pelvis CT scans, which account for tens of millions of studies annually in the United States alone. a2z’s founders emphasize that their AI systems are designed not just to flag individual conditions but to mirror the comprehensive reasoning that expert radiologists apply when interpreting complex studies — a capability that appeals to clinicians and health systems confronting increasing clinical workloads and diagnostic bottlenecks.
The involvement of investors such as Khosla Ventures and SeaX Ventures reflects broader interest in AI applications that extend beyond narrow tasks into more generalist, high-value areas of healthcare. a2z’s strategy to integrate machine learning with clinical workflows taps into growing demand for technologies that can improve operational efficiency, reduce costs associated with diagnostic delays, and ultimately support better patient outcomes. Funding support will also enable the company to explore sustained innovation, including models that could interpret chest, brain, and other advanced imaging types.
Co-founder Pranav Rajpurkar, a Harvard Medical School associate professor known for research in machine learning and medical AI, and CEO Samir Rajpurkar have positioned the company at the convergence of clinical insight and advanced engineering. Their leadership aims to drive adoption of AI systems that can scale across diverse clinical environments, extending the reach of radiologist-level interpretation to hospitals and healthcare facilities that face workforce constraints.
With its $4.5 million seed funding secured, a2z Radiology AI plans a commercial rollout in 2026, leveraging its capital to broaden health system partnerships, enhance its product suite, and continue progress toward its long-term mission: enabling comprehensive, AI-augmented interpretation of medical imaging that reflects the complexity and nuance of real-world clinical practice.
